Research programme: kinase inhibitors - Portola PharmaceuticalsAlternative Names: Dual SYK/JAK inhibitors - Portola; JAK programme - Portola Pharmaceuticals; PRT 0318; PRT 2761; PRT060318; PRT318; Syk kinase inhibitors - Biogen/Portola
Latest Information Update: 19 Feb 2016
At a glance
- Originator Portola Pharmaceuticals
- Class Small molecules
- Mechanism of Action Janus kinase 3 inhibitors; Janus kinase inhibitors; Janus kinase-2 inhibitors; Syk kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Eye disorders; Haematological malignancies; Inflammation
- Discontinued Thrombosis